Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 23 citing articles:

Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease
Matthew Adesuyan, Yogini Jani, Dana Alsugeir, et al.
Neurology (2024) Vol. 102, Iss. 4
Open Access | Times Cited: 22
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Daniela Melchiorri, Sara Merlo, Benjamin Micallef, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 26
Population‐Based Validation Results From the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) Study
Rishi Desai, Vijay R. Varma, Mufaddal Mahesri, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
Dhruv Gohel, Pengyue Zhang, Amit Gupta, et al.
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 2, pp. 643-657
Open Access | Times Cited: 7
Protein Misfolding in Pregnancy: Current Insights, Potential Mechanisms, and Implications for the Pathogenesis of Preeclampsia
Bani Medegan Fagla, Irina A. Buhimschi
Molecules (2024) Vol. 29, Iss. 3, pp. 610-610
Open Access | Times Cited: 6
Optimising the use of electronic medical records for large scale research in psychiatry
Danielle Newby, Niall Taylor, Dan W. Joyce, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Sildenafil and risk of Alzheimer disease: a systematic review and meta-analysis
Wei Yu Chua, Lincoln Kai En Lim, Jianman Wang, et al.
Aging (2025)
Open Access
Phosphodiesterase‑5 inhibitors and Alzheimer’s disease; a meta‑analysis on clinical studies
Saman Behboodi Tanourlouee, Parham Torabinavid, Ali Vaezi, et al.
(2025) Vol. 1, Iss. 1
Open Access
Using Big Data to Uncover Association Between Sildenafil Use and Reduced Risk of Alzheimer’s Disease
Xingyue Huo, Joseph Finkelstein
Studies in health technology and informatics (2023)
Open Access | Times Cited: 9
PDE5 inhibitor drugs for use in dementia
Atticus H. Hainsworth, Ottavio Arancio, Fanny M. Elahi, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 9
A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial
David S. Henry, Richard Pellegrino
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0292863-e0292863
Open Access | Times Cited: 8
Association Between Common Urologic Medications and Onset of Alzheimer’s Disease and Related Dementias in Men With Prostate Cancer Managed by Different Primary Treatment Modalities
Avery Braun, J.E. Cowan, Lindsay A. Hampson, et al.
Urology (2023) Vol. 182, pp. 161-167
Closed Access | Times Cited: 4
Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders
Ashish Kumar, Fred Kim, Dong‐Keun Song, et al.
Aging and Disease (2024)
Open Access | Times Cited: 1
Sildenafil Reverses the Neuropathological Alzheimer’s Disease Phenotype in Cholinergic-Like Neurons Carrying the Presenilin 1 E280A Mutation
Daniela Giraldo-Berrio, Marlene Jiménez-Del-Río, Carlos Velez‐Pardo
Journal of Alzheimer s Disease (2024) Vol. 99, Iss. 2, pp. 639-656
Closed Access | Times Cited: 1
Phosphodiesterase-5 Inhibitors and Dementia Risk: A Real-World Study
Naomi Gronich, Nili Stein, Walid I. Saliba
Neuroepidemiology (2024), pp. 1-10
Open Access | Times Cited: 1
Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
Danielle Newby
Brain Communications (2022) Vol. 4, Iss. 5
Open Access | Times Cited: 3
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Sevil Yaşar, Lolita S. Nidadavolu
Neurology (2024) Vol. 102, Iss. 4
Closed Access
Genetically proxied PDE5 inhibition and risk of dementia: a drug target Mendelian randomisation study
Stephen O. Brennan, Alexander C. Tinworth
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Exploring Trends in Erectile Dysfunction Research from 2017 to 2023: A Focus on COVID-19, Mental Health, Psychiatry, and Drug
Yoshiyasu Takefuji
Sexuality and Disability (2024) Vol. 42, Iss. 2, pp. 521-526
Closed Access
Phosphodiesterase-5 Inhibitors and Dementia Risk: Confounding by Indication in Real-World Studies
Che-Yuan Wu, Walter Swardfager
Journal of Alzheimer s Disease (2024) Vol. 100, Iss. 4, pp. 1161-1163
Closed Access
Drug Repurposing for Effective Alzheimer’s Disease Medicines: Existing Methods and Novel Pharmacoepidemiological Approaches
Jackson A. Roberts, Vijay R. Varma, Attila Jones, et al.
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S299-S315
Closed Access
PDE5 inhibition and Alzheimer's disease risk: a mendelian randomisation study
Marta Alcalde-Herraiz, Benjamin Woolf, Junqing Xie, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Re-Addressing Dementia by Network Medicine and Mechanism-Based Molecular Endotypes
Mayra Pacheco Pachado, Ana I. Casas, Mahmoud H. Elbatreek, et al.
Journal of Alzheimer s Disease (2023) Vol. 96, Iss. 1, pp. 47-56
Open Access
Page 1

Scroll to top